{
    "clinical_study": {
        "@rank": "6386", 
        "arm_group": [
            {
                "arm_group_label": "cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Period 1 (15 days) : ATRIPLA\u2122 Period 2 (21 days) : ATRIPLA\u2122 + oral rifapentine (regimen 1)."
            }, 
            {
                "arm_group_label": "cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Period 1 (15 days) : ATRIPLA\u2122 Period 2 (21 days) : ATRIPLA\u2122 + oral rifapentine (regimen 2)."
            }, 
            {
                "arm_group_label": "cohort 3 (optional)", 
                "arm_group_type": "Experimental", 
                "description": "Period 1 (15 days) : ATRIPLA\u2122 Period 2 (21 days) : ATRIPLA\u2122 + oral rifapentine (regimen 3)."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      - To evaluate the effect of single and repeated administration of rifapentine given as daily\n      or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and\n      tenofovir given as a fixed dose combination (ATRIPLA\u2122 ).\n\n      Secondary Objective:\n\n      - To evaluate the safety and tolerability of concomitant administration of rifapentine and\n      ATRIPLA\u2122  given to HIV+ patients"
        }, 
        "brief_title": "Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA\u2122 in HIV Patients", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "detailed_description": {
            "textblock": "-  Screening to admission: up to 21 days\n\n        -  Admission to the end of the follow-up: up to 41 days\n\n             -  Period 1: Treatment period of 15 days with ATRIPLA\u2122 (background therapy). Patients\n                should receive the same regimen and dose of ATRIPLA\u2122 during the all study\n                screening and period 1.\n\n             -  Period 2: Treatment over a period of 21 days in co-administration with\n                rifapentine.\n\n             -  Follow up: 3 to 5 days after the last rifapentine administration."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n        - HIV+ male and female patients receiving ATRIPLA\u2122 aged 18 to 55 years old with a CD4\n        count cells of at least 350\n\n        Exclusion criteria:\n\n          -  Any history or presence of clinically relevant cardiovascular, pulmonary,\n             gastrointestinal, hepatic, renal, metabolic, haematological (patients with\n             porphyria), neurological, osteomuscular, articular, psychiatric, systemic, ocular,\n             gynaecologic (if female), or infectious disease, or signs of acute illness other than\n             HIV disease.\n\n          -  Active or latent tuberculosis infection\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690403", 
            "org_study_id": "INT12291", 
            "secondary_id": "U1111-1131-1992"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "cohort 3 (optional)", 
                    "cohort 1", 
                    "cohort 2"
                ], 
                "description": "Pharmaceutical form:tablet\nRoute of administration: oral", 
                "intervention_name": "rifapentine (M000473)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "cohort 3 (optional)", 
                    "cohort 1", 
                    "cohort 2"
                ], 
                "description": "Pharmaceutical form:tablet\nRoute of administration: oral", 
                "intervention_name": "EFZ EMT TDF", 
                "intervention_type": "Drug", 
                "other_name": "ATRIPLA\u2122"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rifapentine", 
                "Rifampin", 
                "Tenofovir disoproxil", 
                "Tenofovir", 
                "Efavirenz, emtricitabine, tenofovir disoproxil fumarate drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14202"
                }, 
                "name": "Investigational Site Number 840001"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Non-randomized, Single Sequence, Two Periods, Four-treatment, Three Parallel Groups Pharmacokinetic Interaction Study of Repeated Oral Doses (Daily or Weekly Regimen) of Rifapentine on ATRIPLA\u2122 (Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate) Given to HIV+ Patients", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To determine PK parameters Cmax, Cmin and AUC0-24 for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF)", 
            "safety_issue": "No", 
            "time_frame": "Day-2, Day 1 and Day 21 for cohorts 1 and 3, and on  Day -2 ,Day 1 and Day 16 for cohort 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690403"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To determine PK parameters t1/2z, tmax for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF)", 
                "safety_issue": "No", 
                "time_frame": "Day-2, Day 1 and Day 21  for cohorts 1 and 3, and on Day -2, Day 1 and Day 16 for cohort 2"
            }, 
            {
                "measure": "To determine PK parameters tlag, CL/F for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF)", 
                "safety_issue": "No", 
                "time_frame": "Day-2, Day 1 and Day 21 for cohorts 1 and 3, and on Day -2, Day 1 and Day 16 for cohort 2"
            }, 
            {
                "measure": "To determine PK parameter for AUC0-10 for efavirenz (EFZ), emtricitabine (EMT) and tenofovir (TDF)", 
                "safety_issue": "No", 
                "time_frame": "Day -2 and Day 1 for cohorts 1 and 3"
            }, 
            {
                "measure": "To determine PK parameters Ctrough for rifapentine and 25-desacetyl- rifapentine (25-DR)", 
                "safety_issue": "No", 
                "time_frame": "Cohort 2: Day 1, 8, and 15"
            }, 
            {
                "measure": "To determine PK parameters C8h for rifapentine and 25-desacetyl- rifapentine (25-DR)", 
                "safety_issue": "No", 
                "time_frame": "Cohort 2: Day 1, 8, and 15"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}